Drug Trial Radar · NCT07196163
An Exploratory Study of Golidocitinib in Adult Patients With ITP
Last checked: Nov 20, 2026Latest source record: Sep 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
138
Planned (sponsor's estimate)
Start
Oct 30, 2025
Primary completion
Oct 30, 2028
Study completion Oct 30, 2029
Sponsor
- Lead sponsor
- Peking University People's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter clinical study to evaluate the safety and efficacy of golidocitinib in patients with primary immune thrombocytopenia (ITP). The study consists of two parts: Part A dose escalation and Part B dose expansion. Part A is designed to obtain the safety profile of golidocitinib in patients with ITP and the recommended dose for the randomized cohort in Part B. Part B is a randomized, double-blind, placebo-controlled study, and the primary objective of this part is to evaluate the preliminary efficacy of golidocitinib in patients with ITP.
Conditions
- Immune Thrombocytopenia (ITP)
Interventions
GolidocitinibDrug
Golidocitinib will be administered orally as capsules in a 28-day cycle.
PlaceboDrug
Placebo will be administered orally as capsules in a 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Incidence and severity of Adverse Events (AEs)Time frame: 1 year
- Part B: Durable response rateTime frame: up to 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Insititute of Hematology, Peking University People's Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.